Literature DB >> 1463169

Mortality prediction in infants with congenital diaphragmatic hernia: potential criteria for ECMO.

W Butt1, B Taylor, F Shann.   

Abstract

Over the last ten years the survival of infants born with congenital diaphragmatic hernia who reach the Intensive Care Unit of the Royal Children's Hospital, Melbourne has been constant at 56 +/- 6%. Experimental therapies such as extracorporeal membrane oxygenation, high-frequency oscillation and lung transplantation are now being considered as therapeutic options, and as such the ability to predict survival or death of these infants is increasingly important. The records of all infants with congenital diaphragmatic hernia admitted to the Intensive Care Unit between 1 January 1980 and 30 April 1989 were reviewed; blood gas, ventilatory details, and outcome information was obtained. Receiver operating curve analysis was used to determine the best predictor of death. An oxygenation index (MAP x FiO2/PaO2) > 0.3 or ventilation index (PIP x RR x CO2/1000) > 70 predicted a 94% mortality with a specificity of 96% and a sensitivity of 82%.

Entities:  

Mesh:

Year:  1992        PMID: 1463169     DOI: 10.1177/0310057X9202000406

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Historical aspects of congenital diaphragmatic hernia.

Authors:  P Puri; T Wester
Journal:  Pediatr Surg Int       Date:  1997-02       Impact factor: 1.827

2.  Entry criteria for extracorporeal membrane oxygenation In neonates with congenital diaphragmatic hernia treated with high-frequency oscillatory ventilation.

Authors:  S Kamata; Y Kitayama; H Okuyama; N Usui; T Sawai; S Ishikawa; K Imura; A Okada
Journal:  Pediatr Surg Int       Date:  1996-10       Impact factor: 1.827

3.  Is prognostication in congenital diaphragmatic hernia possible without sophisticated investigations?

Authors:  D Sharma; A Saxena; V K Raina
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.